Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Drotrecogin alfa (activated) (DrotAA), a recombinant human activated protein C (APC), mitigates smoke-induced elevations in pulmonary microvascular permeability and proinflammatory cytokine IL-1β levels in rats. It also inhibits coagulation and inflammation while enhancing fibrinolysis. Drotrecogin alfa (activated) is applicable in severe sepsis research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Drotrecogin alfa (activated) (DrotAA), a recombinant human activated protein C (APC), mitigates smoke-induced elevations in pulmonary microvascular permeability and proinflammatory cytokine IL-1β levels in rats. It also inhibits coagulation and inflammation while enhancing fibrinolysis. Drotrecogin alfa (activated) is applicable in severe sepsis research [1] [2]. |
In vivo | Drotrecogin alfa (activated) administered intravenously at doses up to 20 mg/kg immediately post smoke exposure markedly reduces smoke inhalation injury in a dose-dependent fashion within 2 hours following the event. At a dose of 20 mg/kg, Drotrecogin alfa (activated) enhances the expiratory phase of pulmonary dynamic compliance [2]. |
Molecular Weight | N/A |
CAS No. | 98530-76-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Drotrecogin alfa (activated) 98530-76-8 inhibitor inhibit